Deorphaning anti-tuberculosis compounds using chemogenomic approaches and data from the ChEMBL database
G. Mugumbate, G. Papadatos, J.P. Overington
International Journal of Infectious Diseases · 2014
doi:10.1016/j.ijid.2014.03.834 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background: The emergence of drug resistant strains of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), calls for an urgent need for new drugs that have distinct mechanisms of action. To date, several thousands of active compounds against tuberculosis have been identified through high throughput screening (HTS). The challenge then rests identifying the molecular targets and characterising the mechanism of action of these actives.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.